<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067844</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01382</org_study_id>
    <nct_id>NCT03067844</nct_id>
  </id_info>
  <brief_title>Vascular Effects of Alirocumab in Acute MI-Patients</brief_title>
  <acronym>PACMAN-AMI</acronym>
  <official_title>Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) is the most frequent cause of mortality in the industrialized
      world. Hypercholesterolemia is a major risk factor for the development and progression of
      CAD. While statins currently represent the first-line, gold-standard therapy for primary and
      secondary prevention of cardiovascular morbidity and mortality, nearly 50% of patients in
      Europe and Canada treated with statins do not achieve their target levels of low-density
      lipoprotein cholesterol (LDL-C) or cannot tolerate effective statin doses.

      Recently, a growing number of studies of PCSK9 inhibitors in a wide spectrum of patients with
      hyperlipidemia on or off lipid-lowering therapy, familial hypercholesterolemia, and statin
      intolerance demonstrated consistent, profound, and sustained reductions in LDL-C with greater
      magnitude of reduction as compared with high-dose statin regimens. However, the effects of
      PCSK9 inhibition on coronary plaque morphology remain unknown.

      This study will investigate the effect of the PCSK9 inhibitor alirocumab in patients with
      acute myocardial infarction undergoing percutaneous coronary intervention (PCI) in the
      infarct-related artery and receiving guideline-recommended high-intensity statin therapy. A
      serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical
      coherence tomography imaging study will be performed to determine the change in plaque volume
      at week 52. A total of 220 patients will be enrolled in the study and randomized in a 1:1
      ratio to either alirocumab or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent atheroma volume (PAV)</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in PAV by greyscale intravascular ultrasound (IVUS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total lipid-core burden index (LCBItotal)</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in LCBItotal as determined by near infrared spectroscopy (NIRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum LCBI in any 4-mm segment</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in maximum LCBI in any 4-mm segment (maxLCBI4mm) as determined by NIRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minimal fibrous cap thickness</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in minimal fibrous cap thickness as determined by optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean fibrous cap thickness</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in mean fibrous cap thickness as determined by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average angular extension (AAE) of macrophages</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in AAE of macrophages as determined by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in normalized total atheroma volume (NTAV)</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in NTAV by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-cholesterol</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in hsCRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity troponin T (hsTnT)</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in hsTnT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP)</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in NT-pro-BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in further biomarkers</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Change in lipid and inflammatory markers and their association with indices of plaque progression/regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Any death, cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Any non-fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven coronary revascularization</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Any ischemia-driven coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>Any ischemic stroke/transient ischemic attack</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Coronary Vessel</condition>
  <condition>Coronary Circulation</condition>
  <condition>Atheroma; Myocardial</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab 150 mg/mL</intervention_name>
    <description>Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50.</description>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ≥18 years at screening;

          -  Acute myocardial infarction: acute ST-segment elevation myocardial infarction (STEMI)
             with pain onset within ≤24h, or non-ST segment elevation myocardial infarction
             (NSTEMI), with at least one coronary segment (culprit lesion) requiring PCI;

          -  LDL-C ≥70 mg/dL (≥1.8 mmol/L) assessed prior to, or during PCI in patients who have
             been receiving any stable statin regimen within ≥ 4 weeks prior to enrollment; OR
             LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on
             stable statin regimen for ≥ 4 weeks prior to enrollment;

          -  At least two major native coronary arteries (&quot;target vessels&quot;) each meeting the
             following criteria for intracoronary imaging immediately following the qualifying PCI
             procedure: Angiographic evidence of &lt;50% reduction in lumen diameter by angiographic
             visual estimation;

          -  Target vessel deemed to be accessible to imaging catheters and suitable for
             intracoronary imaging in the proximal (50mm) segment (&quot;target segment&quot;);

          -  Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed
             native vessel;

          -  Target vessel must not have undergone previous PCI within the target segment;

          -  Target vessel is not candidate for intervention at the time of qualifying PCI or over
             the following 6 months in the judgment of the Investigator;

          -  Hemodynamic stability allowing the repetitive administration of nitroglycerine;

          -  Ability to understand the requirements of the study and to provide informed consent;

          -  Willingness to undergo follow-up intracoronary imaging.

        Exclusion Criteria:

          -  Left-main disease, defined as ≥50% reduction in lumen diameter of the left main
             coronary artery by angiographic visual estimation;

          -  Three-vessel disease, defined as ≥70% reduction in lumen diameter of three major
             epicardial coronary arteries by angiographic visual estimation or in major branches of
             one or more of these arteries, irrespective of the localization (proximal 50mm or more
             distal localization) of the obstructive lesions;

          -  History of coronary artery bypass surgery;

          -  &quot;Thrombolysis In Myocardial Infarction&quot; (TIMI) flow &lt;2 of the infarct-related artery
             after PCI;

          -  Unstable clinical status (hemodynamic or electrical instability);

          -  Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT
             evaluation;

          -  Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular
             tachycardia or atrial fibrillation with rapid ventricular response not controlled by
             medications in the past 3 months prior to screening;

          -  Severe renal dysfunction, defined by estimated glomerular filtration rate &lt;30
             ml/min/1.73m2;

          -  Active liver disease or hepatic dysfunction;

          -  Known intolerance to rosuvastatin OR known statin intolerance;

          -  Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;

          -  Known sensitivity to any substances to be administered, including known statin
             intolerance;

          -  Patients who previously received alirocumab or other PCSK9 inhibitor;

          -  Patient who received cholesterol ester transfer protein inhibitors in the past 12
             months prior to screening;

          -  Treatment with systemic steroids or systemic cyclosporine in the past 3 months;

          -  Known active infection or major hematologic, metabolic, or endocrine dysfunction in
             the judgment of the Investigator;

          -  Planned surgery within 12 months;

          -  Patients who will not be available for study-required visits in the judgment of the
             Investigator;

          -  Current enrollment in another investigational device or drug study;

          -  History of cancer within the past 5 years, except for adequately treated basal cell
             skin cancer, squamous cell skin cancer, or in situ cervical cancer;

          -  Estimated life expectancy less than 1 year;

          -  Female of childbearing potential (age &lt;50 years and last menstruation within the last
             12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenz Raeber, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern Universitiy Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenz Raeber, Prof., MD</last_name>
    <phone>+41 31 632 09 29</phone>
    <email>lorenz.raeber@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Frenk, PhD</last_name>
    <phone>+41 31 632 19 16</phone>
    <email>andre.frenk@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Kaiser, Prof., MD</last_name>
      <phone>+41 61 556 58 16</phone>
      <email>christoph.kaiser@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenz Räber, MD</last_name>
      <phone>+41 31 632 09 29</phone>
      <email>lorenz.raeber@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Konstantinos Koskinas, MD</last_name>
      <phone>+41 31 632 45 56</phone>
      <email>konstantinos.koskinas@insel.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Rigamonti, MD</last_name>
      <phone>+41 79 55 34 218</phone>
      <email>Fabio.rigamonti@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crochan J O'Sullivan, MD</last_name>
      <phone>+41 44 416 33 58</phone>
      <email>Crochan.oSullivan@triemli.zuerich.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12. Erratum in: J Am Coll Cardiol. 2015 Dec 22;66(24):2812. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024-3025.</citation>
    <PMID>24239923</PMID>
  </results_reference>
  <results_reference>
    <citation>Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16.</citation>
    <PMID>25687353</PMID>
  </results_reference>
  <results_reference>
    <citation>Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.</citation>
    <PMID>26330422</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.</citation>
    <PMID>25773378</PMID>
  </results_reference>
  <results_reference>
    <citation>Koskinas KC, Ughi GJ, Windecker S, Tearney GJ, Räber L. Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. Eur Heart J. 2016 Feb 7;37(6):524-35a-c. doi: 10.1093/eurheartj/ehv642. Epub 2015 Dec 11. Review.</citation>
    <PMID>26655874</PMID>
  </results_reference>
  <results_reference>
    <citation>Räber L, Taniwaki M, Zaugg S, Kelbæk H, Roffi M, Holmvang L, Noble S, Pedrazzini G, Moschovitis A, Lüscher TF, Matter CM, Serruys PW, Jüni P, Garcia-Garcia HM, Windecker S; IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416). Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2015 Feb 21;36(8):490-500. doi: 10.1093/eurheartj/ehu373. Epub 2014 Sep 2.</citation>
    <PMID>25182248</PMID>
  </results_reference>
  <results_reference>
    <citation>Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, Maini B, Biro S, Lee JB, Stone GW, Weisz G, Maehara A. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J. 2012 Feb;33(3):372-83. doi: 10.1093/eurheartj/ehr387. Epub 2011 Oct 20.</citation>
    <PMID>22019821</PMID>
  </results_reference>
  <results_reference>
    <citation>Maehara A, Cristea E, Mintz GS, Lansky AJ, Dressler O, Biro S, Templin B, Virmani R, de Bruyne B, Serruys PW, Stone GW. Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S1-9. doi: 10.1016/j.jcmg.2011.11.019.</citation>
    <PMID>22421222</PMID>
  </results_reference>
  <results_reference>
    <citation>Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, Sum ST, Kini A, Sharma S, Rizik D, Brilakis ES, Shunk KA, Petersen J, Weisz G, Virmani R, Nicholls SJ, Maehara A, Mintz GS, Stone GW, Muller JE. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013 Aug;6(8):838-46. doi: 10.1016/j.jcin.2013.04.012. Epub 2013 Jul 17.</citation>
    <PMID>23871513</PMID>
  </results_reference>
  <results_reference>
    <citation>Räber L, Zanchin T, Baumgartner S, Taniwaki M, Kalesan B, Moschovitis A, Garcia-Garcia HM, Justiz J, Pilgrim T, Wenaweser P, Meier B, Jüni P, Windecker S. Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol. 2014 May 1;173(2):259-67. doi: 10.1016/j.ijcard.2014.02.036. Epub 2014 Feb 28.</citation>
    <PMID>24631113</PMID>
  </results_reference>
  <results_reference>
    <citation>Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Räber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72. doi: 10.1016/j.jacc.2011.09.079. Erratum in: J Am Coll Cardiol. 2012 May 1;59(18):1662. Dudeck, Darius [corrected to Dudek, Darius]; Falk, Erlin [corrected to Falk, Erling]; Garcia, Hector [corrected to Garcia-Garcia, Hector M]; Sonada, Shinjo [corrected to Sonoda, Shinjo]; Troels, Thim [corrected to Thim, Troels]; van Es, Gerrit-Ann [corrected to van Es, Gerrit-Anne].</citation>
    <PMID>22421299</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

